risedronic acid has been researched along with Ache in 17 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although etidronate is effective, risedronate offers a shorter duration of therapy, better and longer-lasting remission, significant reductions in pain, and provides additional remission in subjects who exhibited an incomplete response to previous etidronate treatment." | 5.09 | A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. ( Axelrod, DW; Bekker, PJ; Brown, JP; Hoseyni, MS; Miller, PD; Siris, ES, 1999) |
| "Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis." | 2.76 | Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. ( Fujii, Y; Fujita, T; Miyauchi, A; Nakajima, M; Ohue, M; Takagi, Y, 2011) |
| "After the pain is resolved and the examination shows improvement, patients may gradually increase their level of activity." | 2.47 | Stress fractures: diagnosis, treatment, and prevention. ( Kapil, N; Patel, DS; Roth, M, 2011) |
| "Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment." | 1.38 | The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012) |
| "Risedronate decreased bone cancer-related bone destruction and pain-related behavior and decreased the spinal expression of glial fibrillary acidic protein, whereas NE-10790 had no effect on these parameters." | 1.35 | Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. ( Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW, 2009) |
| "Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120." | 1.32 | Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. ( Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Imai, T | 1 |
| Tanaka, S | 1 |
| Kawakami, K | 1 |
| Miyazaki, T | 1 |
| Hagino, H | 1 |
| Shiraki, M | 1 |
| Hald, A | 1 |
| Hansen, RR | 1 |
| Thomsen, MW | 1 |
| Ding, M | 1 |
| Croucher, PI | 1 |
| Gallagher, O | 1 |
| Ebetino, FH | 1 |
| Kassem, M | 1 |
| Heegaard, AM | 1 |
| Fujita, T | 1 |
| Ohue, M | 1 |
| Nakajima, M | 1 |
| Fujii, Y | 1 |
| Miyauchi, A | 1 |
| Takagi, Y | 1 |
| Patel, DS | 1 |
| Roth, M | 1 |
| Kapil, N | 1 |
| Meulenbeld, HJ | 1 |
| van Werkhoven, ED | 1 |
| Coenen, JL | 1 |
| Creemers, GJ | 1 |
| Loosveld, OJ | 1 |
| de Jong, PC | 1 |
| Ten Tije, AJ | 1 |
| Fosså, SD | 1 |
| Polee, M | 1 |
| Gerritsen, W | 1 |
| Dalesio, O | 1 |
| de Wit, R | 1 |
| Nakamura, T | 1 |
| Osawa, M | 1 |
| Itoh, M | 1 |
| Yamaguchi, H | 1 |
| Iinuma, N | 1 |
| Hayakawa, Y | 1 |
| Suzuki, H | 1 |
| Kamisaki, T | 1 |
| Iwayama, S | 1 |
| Nishikawa, M | 1 |
| Minne, HW | 1 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Rendina, D | 1 |
| Mossetti, G | 1 |
| Viceconti, R | 1 |
| Sorrentino, M | 1 |
| Nunziata, V | 1 |
| Wysowski, DK | 1 |
| Chang, JT | 1 |
| Wright, SA | 1 |
| Millar, AM | 1 |
| Coward, SM | 1 |
| Finch, MB | 1 |
| Carvalho, AP | 1 |
| Bezerra, MM | 1 |
| Girão, VC | 1 |
| Cunha, FQ | 1 |
| Rocha, FA | 1 |
| Bingham, CO | 1 |
| Buckland-Wright, JC | 1 |
| Garnero, P | 1 |
| Cohen, SB | 1 |
| Dougados, M | 1 |
| Adami, S | 1 |
| Clauw, DJ | 1 |
| Spector, TD | 1 |
| Pelletier, JP | 1 |
| Raynauld, JP | 1 |
| Strand, V | 1 |
| Simon, LS | 1 |
| Meyer, JM | 1 |
| Cline, GA | 1 |
| Beary, JF | 1 |
| Felson, DT | 1 |
| Kim, YJ | 1 |
| Hosking, DJ | 1 |
| Eusebio, RA | 1 |
| Chines, AA | 1 |
| Miller, PD | 2 |
| Brown, JP | 1 |
| Siris, ES | 1 |
| Hoseyni, MS | 1 |
| Axelrod, DW | 1 |
| Bekker, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836] | Phase 1 | 56 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for risedronic acid and Ache
| Article | Year |
|---|---|
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
Stress fractures: diagnosis, treatment, and prevention.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Calcium, Diet | 2011 |
The futility of current approaches to chondroprotection.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Doxycyc | 2007 |
The use of risedronate in Paget's disease.
Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia, | 1999 |
5 trials available for risedronic acid and Ache
8 other studies available for risedronic acid and Ache
| Article | Year |
|---|---|
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.
Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone | 2009 |
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; | 2012 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Toleran | 2004 |
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone and Bones; Child; Etidroni | 2005 |
Chronic diffuse sclerosing osteomyelitis treated with risedronate.
Topics: Adult; Calcium Channel Blockers; Chronic Disease; Etidronic Acid; Female; Humans; Osteomyelitis; Pai | 2005 |
Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Diphosphonates; | 2006 |
Paget's disease of bone: reduction of disease activity with oral risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Calcium Channel Blocke | 1998 |